Debio-0123 is under clinical development by Debiopharm International and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Debio-0123’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Debio-0123 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Debio-0123 overview

Debio-0123 (ADC-730) is under development for the treatment of advanced solid tumors. The drug candidate is administered orally as a capsule. It acts by targeting WEE-1, a nuclear protein kinase. It was also under development for the treatment of colon and lung adenocarcinoma.

Debiopharm International overview

Debiopharm International, a subsidiary of Debiopharm Group, focuses on development and manufacture of drugs for oncology and bacterial infections. The company offers Oxaliplatin and Triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections, and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.

Quick View Debio-0123 LOA Data

Report Segments
  • Innovator
Drug Name
  • Debio-0123
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.